MedTrace Logo

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

NCT05245500 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2025-12-05

No results posted yet for this study

Summary

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Conditions

  • Mesothelioma
  • Non Small Cell Lung Cancer
  • Malignant Peripheral Nerve Sheath Tumors
  • Solid Tumor
  • Pancreatic Adenocarcinoma
  • Advanced Solid Tumor

Interventions

DRUG

MRTX1719

MRTX1719 is a potent PRMT5-MTA inhibitor. Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-09
Primary Completion
2027-12-10
Completion
2027-12-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05245500 on ClinicalTrials.gov